Navigation Links
Drug discovery programs boosted
Date:12/2/2010

Dec 03, 2010, Seoul, S. Korea Institut Pasteur Korea (IP-K) has signed an agreement with sanofi-aventis Research & Development of Toulouse, France to continue research on the identification of new medicines.

The partnership, extending an agreement drawn up in the fall of 2009, illustrates the value of IP-K's PhenomicScreen to the pharmaceutical industry. The technology platform will be used to pinpoint active, non-toxic agents in sanofi-aventis' proprietary chemical compound library.

The high-throughput, high-content visual screening approach of PhenomicScreen is well suited to identifying lead compounds. Dr. Priscille Brodin of IP-K explains that "Our phenotypic approach does not rely on a predefined target, but rather simultaneously selects both chemical compounds and an unknown cellular target solely by the clearly discernible effect on the disease model". The advantage, according to IP-K's Dr. Jonathan Cechetto, is that "The process has the ability to select novel targets, and only those which are functionally significant in the disease process".

Commenting on the new agreement with sanofi-aventis, Laurent Fraisse, director of infectious diseases research said "Over the past year the collaboration has made important strides in identifying potential new drugs, and we are pleased to extend our agreement with IP-K."

Center Director of Core Technologies of Institut Pasteur Korea Dr. Veronica Soloveva believes that the agreement is a vindication of the institute's innovative approach to drug discovery. "Phenomic technology increases the accuracy and speed of drug discovery", she said, "And we are delighted to be working with sanofi-aventis to accelerate their identification of new compounds".


'/>"/>

Contact: Jean Kim
babunn@ip-korea.org
82-318-018-8041
Institut Pasteur Korea
Source:Eurekalert

Page: 1

Related biology news :

1. Chemical equator discovery will aid pollution mapping
2. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
3. Groundbreaking discovery may lead to stronger antibiotics
4. Discovery of natural compounds that could slow blood vessel growth
5. Nanoscopic screening process to speed drug discovery
6. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
7. New $11 million center to speed production of new compounds for drug discovery
8. Discovery of giant roaming deep sea protist provides new perspective on animal evolution
9. New discovery may enhance MRI scans, lead to portable MRI machines
10. Kidney function discovery sheds light on genetic complexity of disease
11. Discovery of new gene associated with diabetes risk suggests link with body clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... 2015 The latest 364 page report ... of the global border security market . Visiongain ... in 2015. Now: Border security is hard to ... the business critical issue you need to know about - ... objective analysis of how this will impact your company and ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... protein regulates secretion levels in the fruit fly's salivary ... the May 15 issue of Development, the finding improves ... is a critical ability of certain glands and cell ... researchers discovered that a protein called CrebA single-handedly controls ...
... skin cancer, researchers at the Huntsman Cancer Institute at the ... gene found in up to 30 percent of human tumors. ... in cell signaling, or communication among cells. When mutated, however, ... shown to promote the growth of cancers in the pancreas, ...
... gene therapy can promote the growth of new "insulation" around ... new study shows. The treatment, which mimics the activity of ... and electrical conduction from the brain to the leg muscles. ... spinal cord injury in humans. The study was funded in ...
Cached Biology News:Study: Well-known protein helps stem cells become secretory cells 2Scientists inhibit cancer gene 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... BEIJING , August 26, 2015 Israel ... DiaCardio wins 1 st place  Wayerz comes ... in Israel by venture capital fund JVP, ... including the US, China , Israel ... America .  Impressive achievement for the Israeli representatives ...
(Date:8/26/2015)... 26, 2015 After litigating and negotiating ... relating to P2i United States patent ... in the United States without any ... of either party. As a result of the parties, settlement, ... California dismissed the case without prejudice. ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial ... with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to ... regulatory pathways., , Stem Cell Meeting on the Mesa ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Pharmos Corporation,(Nasdaq: PARS ) today reported results for the ... loss of $2.7 million, or $0.10 per share,for the second ... or,$0.18 per share, in the second quarter 2007. Cash and ... decrease in net loss for the second quarter 2008 is ...
... Aug. 7 Anesiva,Inc. (Nasdaq: ANSV ) today ... six months ended June 30, 2008., "The 2008 ... we,introduced Zingo(TM) in the U.S. pediatric hospital market," said ... I,m pleased,to report that our Phase 3 trials of ...
... announced that it,has extended its current offer to purchase ... Purchase Warrants, Class 1 and Class B Common Stock,Purchase ... time, on,Friday, August 15, 2008. The offer was scheduled ... August 7, 2008., The extension will provide Warrant ...
Cached Biology Technology:Pharmos Corporation Reports 2008 Second Quarter Results 2Pharmos Corporation Reports 2008 Second Quarter Results 3Pharmos Corporation Reports 2008 Second Quarter Results 4Pharmos Corporation Reports 2008 Second Quarter Results 5Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... degradation of single-stranded DNA and RNA endonucleolytically ... nuclease prefers ssDNA over dsDNA by 30,000-fold, ... double-stranded DNA from both ends (1,2). Mung ... mapping studies (3,4), for flushing staggered ends ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: